文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > 2014 TO P Modulation of gamma globin genes expression by histone deacetylase Inhibitors
侵权投诉

2014 TO P Modulation of gamma globin genes expression by histone deacetylase Inhibitors

HbInductionbyHistoneDeacetylaseInhibitor

inhibitorsdeterminethehyperacetylationofe-aminogroupsoflysineresiduesofhistones,andthismodi cationinturnleadstoareducedinteractionbetweencorehistoneproteinsandDNAinthepromoterregionofcertaingenesdetermin-ingtheirtranscriptionalactivation(Atweh&Loukopoulos,2001).However,othermechanismsnotdirectlyinvolvingmodi cationatthelevelofHBG1/2promotersmayoccur.Apicidin,apotentHDACinhibitor,hasbeendescribedtomodulatethep38MAPKpathwayinvolvedinerythropoie-tin-inducederythroiddifferentiation(Wittetal,2003;Testa,2009).Moreover,HDACs,mainlyHDAC1andHDAC2,arecomponentsofthetranscriptionalrepressioncomplexSIN3-HDAC-NuRD-BCL11A,sothatthepharmacologicaldown-regulationofBCL11AcouldresultintheinductionofHBG1/2expression(Bradneretal,2010;Bauer&Orkin,2011;Sankaran,2011).

Histonedeacetylasesarerecruitedbyandinteractwithavari-etyoftranscriptionalfactorsinvolvedinglobingeneregulation,sothatHDACinhibitorscouldmodulateglobingeneexpressionindirectlythroughtheregulationoftherecruitmentofcoactiva-torandcorepressorcomplexes.HowtheinterplaybetweenHDACsandtranscriptionalfactorsandcofactorsexertitseffectsonglobinchromatinandresultintranscriptionalsilencingoractivationoftheglobingenesisstillunclear.FurtherstudiesareneededtounderstandtheexactmechanismsofactionofGVSandtoinvestigateallthegeneswhoseexpressionismodulatedbyGVS.Thisisofparticularimportance,asoneofthemajorlimitationstotheuseofHDACinhibitorsinvivoisthewidevarietyofrolesplayedbythesecompoundsinanumberoftis-sues,sothattoxicitycouldbeamajorproblembeforeHb-inductiveeffectsareseen(Sankaran,2011).

Asmentionedearlier,GVShasagoodsafetypro lewhengiventooncologicalpatients.AdverseeventsinducedbyHDACinhibitorsaregenerallywellmanagedinsuchpatients,however,chronicadministrationofthesecom-poundsmayrepresentaprobleminnon-oncologicalpathol-ogies,suchasSCDandb-thalassaemia.OurinvitrodatausingGVSasapossibleinducerofHBG1/2indicatethatthecompoundisactiveatconcentrationsaslowas1nmol/l.Thisconcentrationisreadlyachievableinvivoinhumansfol-lowingadministrationofalowdosageofGVS.Infact,afterasingleoraladministrationof50mgofGVS,theplasmalevelpersistsabovethisconcentrationforatleast8–10h(Furlanetal,2011)suggestingthatevenalowerdosecouldbeadministeredtomaintainthisconcentration.

Inasmalltrialinsystemic-onsetjuvenileidiopathicarthri-tis,children(meanage,11Á6years)weretreatedwithGVSat

adoseof1Á5mg/kg/d(0Á75mg/kgat12-hintervals)for12weeks.Thedrugshowedagoodsafetypro lewithmildadverseevents,whichwerereversibleandofshortduration(Vojinovic&Damjanov,2011).Assessmentofsafetywastheprimaryendpointofthetrialbuttheauthorsalsoreportedsignsofef cacy,asjudgedbyAmericanCollegeofRheuma-tology(ACR)Pediatric(ACRPedi)30,ACRPedi50andACRPedi70improvementaswellasimprovementsinmobilityandwell-beingofthepatients.Furthermore,toourknowledge,GVSiscurrentlytheonlyHDACinhibitorallowedtobeadministeredtochildren.

LiteraturedatashowthatlowdosesofHDACinhibitorshavevariouspharmacologicalactivitiesmeasuredinnormalcellswithoutshowingtoxiceffects(Furlanetal,2011;Vojinovic&Damjanov,2011).Thelatteraresometimesobservedatgreaterdosesneededtoachieveananti-tumoureffect,thuslimitingthetherapeuticwindowofsomeHDACinhibitors.TheexploitationofthepharmacologicalactivityexertedbyHDACinhibitorsatlow,non-antitumourconcen-trationsisstillinitsinfancy,butitdeservesamoreaccurateandwidespreadexamination.ClinicalexperiencewithGVSsuggeststhatlowdoseofthisdrugcouldbeadministeredwithoutserioussideeffects.

Notwithstandingthelimitationdiscussedabove,ourresultssuggestthatGVSisamoleculeworthyoffurtherinvestigationasanHbinducer.Tobetterevaluatethepossi-bleinvivouseofthemolecule,studieswithmurinemodelsofSCD/b-thalassaemiaarerequired.Inaddition,otherdis-easesassociatedwithineffectiveerythropoiesis,suchascon-genitaldyserythropoieticanaemias,couldbeanotherpossibletherapeutictargetofGVSaswellasnovelHDACinhibitors.

Acknowledgements

L.R.:designedtheresearchstudy,performedtheinvitroexperiments,analysedthedataandwrotethepaper;L.S.:performedtheresearch,contributedtodataanalysisanddraftingofthemanuscript;G.F.:designedtheresearchstudy,analysedthedataandwrotethepaper;D.M:performedtheresearch,contributedtodataanalysis;E.T:performedthecyto uorimetricexperiments;L.P.:performedthecyto uori-metricexperimentsandcontributedtodataanalysis;M.D.C.:designedtheresearchstudy,contributedtodataanalysisandsupervisedthemanuscript.ThisstudywassupportedbyItal-farmaco,S.p.A.GFandDMareemployeesofItalfarmaco,whichproducesGivinostat/ITF2357.Theotherauthorsdeclarenocompeting nancialinterests.

References

Akinsheye,I.,Alsultan,A.,Solovieff,N.,Ngo,D.,Baldwin,C.T.,Sebastiani,P.,Chui,D.H.K.&Steinberg,M.H.(2011)Fetalhemoglobininsicklecellanemia.Blood,118,19–27.

Atweh,G.F.&Fathallah,H.(2010)Pharmacologicinductionoffetalhemoglobinproduction.Hematology/OncologyClinicsofNorthAmerica,24,1131–1144.

Atweh,G.F.&Loukopoulos,D.(2001)Pharmaco-logicalinductionoffetalhemoglobininsicklecelldiseaseandbeta-thalassemia.SeminarsinHematology,38,367–373.

Bakanay,S.M.,Dainer,E.,Clair,B.,Adekile,A.,Daitch,L.,Wells,L.,Holley,L.,Smith,D.&Kutlar,A.(2005)Mortalityinsicklecellpatientsonhydroxyureatherapy.Blood,105,545–547.

ª2014JohnWiley&SonsLtd,BritishJournalofHaematology7

上一页第7页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email